srRNA Vaccine for HIV
HIV Prevention
Pre-clinicalActive
Key Facts
About Replicate Bioscience
Replicate Bioscience is a private, pre-revenue biotech firm developing a proprietary self-replicating RNA (srRNA) platform. The technology is engineered to use the cell's own machinery to repeatedly produce therapeutic RNA, leading to significantly higher and more durable protein expression than standard mRNA. The company is advancing a pipeline of srRNA candidates across infectious disease, oncology, and autoimmune indications, positioning itself to address limitations of current RNA therapeutics. Recent milestones include grant funding for vaccine development and key leadership appointments.
View full company profileTherapeutic Areas
Other HIV Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Lenacapavir | Gilead Sciences | Phase 3 |
| Cabotegravir (LA) for PrEP | ViiV Healthcare | Approved/Phase 3 |
| GRAdHIVNE1 | ReiThera | Phase 1 |